Clinical trials: SCN8A Developmental and Epileptic Encephalopathy Syndrome

SCN8A Developmental and Epileptic Encephalopathy Syndrome

Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

• Terminated
• Age: 2 to 21 years
• Phase 2
• Results posted

The objective of this study is to assess the efficacy, safety, and pharmacokinetics of NBI-921352 as adjunctive therapy for seizures in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).

Trial name

NCT04873869

Testing

NBI-921352

Where

4 sites in United States

Volunteers

8 people

Sponsor

Neurocrine Biosciences